A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.

A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.

We initiated a prospective trial to identify transcriptional alterations associated with acquired chemotherapy resistance from pre- and post-biopsy samples from the same patient and uncover potential molecular pathways involved in treatment failure to help guide therapeutic alternatives.A prospectiv...

Full description

Bibliographic Details
Main Authors:	Hark Kyun Kim, Il Ju Choi, Chan Gyoo Kim, Hee Sung Kim, Akira Oshima, Aleksandra Michalowski, Jeffrey E Green
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2011-02-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3041770?pdf=render

Similar Items

Modified DCF (Docetaxel, Cisplatin and 5-fluorouracil) chemotherapy is effective for the treatment of advanced rectal squamous cell carcinoma
by: Laure Hervé, et al.
Published: (2022-11-01)

Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer
by: Jin Ye Fu, et al.
Published: (2023-02-01)

The Effectiveness of Hepatic Arterial Infusion Chemotherapy with 5-Fluorouracil/Cisplatin and Systemic Chemotherapy with Ramucirumab in Alpha-Fetoprotein-Producing Gastric Cancer with Multiple Liver Metastases
by: Yasuhiro Doi, et al.
Published: (2018-01-01)

Relationship between the Expression of the Thymidylate Synthase and the Prognosis of Gastric Cancer Patients Treated with Combinational Chemotherapy Regimen Including Fluorouracil, Docetaxel and Cisplatin
by: Mozaffar Aznab, et al.
Published: (2020-07-01)

Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
by: Ying-Tao Lin, et al.
Published: (2023-11-01)

Cisplatin for cancer therapy and overcoming chemoresistance
by: Ranmali Ranasinghe, et al.
Published: (2022-09-01)

Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.
by: Xiao-Long Chen, et al.
Published: (2013-01-01)

Low‐dose 5‐fluorouracil/cisplatin therapy as conversion chemotherapy for advanced extramammary Paget's disease
by: Kento Nakamura, et al.
Published: (2020-04-01)

Adjuvant chemoradiotherapy combined with cisplatin, 5-fluorouracil and folinic acid for locally advanced gastric cancer
by: Muharrem Kocar, et al.
Published: (2016-04-01)

The results of primary chemotherapy of TS-1/cisplatin regimen in unresectable or metastatic gastric cancer patients
by: Jung Hyun Song, et al.
Published: (2014-06-01)

Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis
by: Yuji Akiyama, et al.
Published: (2018-07-01)

ATR activated by EB virus facilitates chemotherapy resistance to cisplatin or 5-fluorouracil in human nasopharyngeal carcinoma
by: Zhang B, et al.
Published: (2019-01-01)

Chemoresistance mechanisms to 5-Fluorouracil and reversal strategies in lung and breast cancer
by: Chunge Zhong, et al.
Published: (2025-02-01)

Caveolin-1 Promotes Chemoresistance of Gastric Cancer Cells to Cisplatin by Activating WNT/β-Catenin Pathway
by: Xi Wang, et al.
Published: (2020-02-01)

The efficacy and safety of 5-fluorouracil/cisplatin/vincristine as a multi-agent chemotherapy regimen in gestational trophoblastic neoplasia
by: Lu Wang, et al.
Published: (2023-10-01)

Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas
by: Vanessa de Carvalho Fabrício, et al.

A High-Resolution Mass Spectrometry-Based Quantitative Metabolomic Workflow Highlights Defects in 5-Fluorouracil Metabolism in Cancer Cells with Acquired Chemoresistance
by: Sanjay Shahi, et al.
Published: (2020-05-01)

Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma
by: Sai-Lan Liu, et al.
Published: (2018-12-01)

Preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal carcinosarcoma: a case report and review of the literature
by: Tomoko Yoshimoto, et al.
Published: (2018-02-01)

Efficacy of docetaxel, cisplatin, and 5-fluorouracil as an induction chemotherapy in oral squamous cell carcinoma in a tertiary hospital in Saudi Arabia
by: Mohammad Alessa, et al.
Published: (2024-01-01)

Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer
by: Hung-Ming Wang, et al.
Published: (2017-03-01)

Silencing of NLRP3 Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin
by: Weijia Li, et al.
Published: (2023-01-01)

VPS33B suppresses lung adenocarcinoma metastasis and chemoresistance to cisplatin
by: Zhen Liu, et al.
Published: (2021-05-01)

circ-LDLRAD3 Knockdown Reduces Cisplatin Chemoresistance and Inhibits the Development of Gastric Cancer with Cisplatin Resistance through miR-588 Enrichment-Mediated SOX5 Inhibition
by: Qianping Liang, et al.
Published: (2023-05-01)

Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer
by: Sheng Zhang, et al.
Published: (2019-01-01)

Error-prone translesion synthesis mediates acquired chemoresistance
by: Xie, Kun, et al.
Published: (2014)

Ganoderma spore lipid ameliorates docetaxel, cisplatin, and 5-fluorouracil chemotherapy-induced damage to bone marrow mesenchymal stem cells and hematopoiesis
by: Haohui Lin, et al.
Published: (2024-04-01)

<i>DPYD</i> and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
by: Theodore J. Wigle, et al.
Published: (2019-05-01)

Cisplatin and Short-Term 5-Fluorouracil Infusion for Paraneoplastic Microangiopathic Hemolytic Anemia in Gastric Cancer: A Case Report and Review of the Literature
by: M. S. Sanatani, et al.
Published: (2013-01-01)

Cellular and Molecular Mechanisms of Chemoresistance for Gastric Cancer
by: Li Z, et al.
Published: (2024-08-01)

The Expression of ZNF268 and Its Role in The Cisplatin-based Chemoresistance of Breast Cancer
by: Weilu Wu, et al.
Published: (2023-08-01)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
by: Peng Liu, et al.
Published: (2022-12-01)

Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced head and neck squamous cell carcinoma: A real-world data study
by: Matheus Yung Perin, et al.
Published: (2025-05-01)

Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1
by: Joo Young Jung, et al.
Published: (2016-01-01)

Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma
by: Nobukazu Hokamura, et al.
Published: (2024-09-01)

The outcomes of intensified 5-fluorouracil plus leucovorin chemotherapy for preoperative chemoradiation in rectal cancers
by: Neul Ha, et al.
Published: (2017-12-01)

Pharmacological NF‐κB inhibition decreases cisplatin chemoresistance in muscle‐invasive bladder cancer and reduces cisplatin‐induced toxicities.
by: Rui M. Gil da Costa, et al.
Published: (2023-12-01)

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
by: Bang Soo-Mee, et al.
Published: (2006-01-01)

Long-term results of locoregionally advanced nasopharyngeal carcinoma treated with cisplatin and 5-fluorouracil induction chemotherapy with or without docetaxel in young and middle aged adults
by: Yuming Zheng, et al.
Published: (2025-03-01)

EPLIN Expression in Gastric Cancer and Impact on Prognosis and Chemoresistance
by: Wenjing Gong, et al.
Published: (2021-04-01)